Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Skandia Investment and Investor Growth Capital acquire Swedish Orphan International
Mandate

Skandia Investment and Investor Growth Capital acquire Swedish Orphan International

May 12, 2005

A consortium comprising of Investor Growth Capital (IGC), Skandia Investment (SI), the Swedish private equity firms and the CEO of Swedish Orphan International AB (SOI) have agreed to acquire the company. SOI is a Sweden based company with the business concept to develop, register, market and distribute orphan drugs, which are pharmaceuticals used in the treatment of rare disorders, for an undisclosed sum.

Vinge acted for Investor Growth Capital and Skandia Investment.
Ulf Sallnäs (responsible partner)
Helena Dandenell, Kristoffer Persson (associates)

Related

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026

Vinge advises on the sale of Compab to Tången

 Vinge has advised the owners of Compab Energiteknik in connection with the sale of 80 per cent of the shares to Tången Industrikapital. Compab, which has a turnover of approximately SEK 100 million, sells, installs and services, amongst other things, steam and hot-water boilers as well as burners for the industrial sector.
October 26, 2026